We are currently partnering with multiple institutions to run statistical analyses on existing datasets that contain aggregate data on psychedelic use.
We plan to fund and conduct a randomized controlled clinical trial:
- Please see link for proposed clinical trial – Click here
- We will need to raise approximately $500,000 USD to carry out this clinical trial
- After we raise all necessary funds, we will begin recruitment for the clinical trial
We support rescheduling psychedelic drugs out of Schedule 1 so as to allow for more research on psychedelics.
In addition to carrying out clinical research and advocating for rescheduling, our goal is to provide evidence-based, trauma-informed psychedelic-assisted therapy, regardless of socioeconomic status.
We will begin offering therapy after MDMA and/or psilocybin become FDA-approved.
Read about our past, current, and future clinical trials.